Selected article for: "effective vaccine and major role"
Author: Lee, Na-Kyoung; Paik, Hyun-Dong
Title: Prophylactic effects of probiotics on respiratory viruses including COVID-19: a review
  • Cord-id: yisghbfq
  • Document date: 2021_5_24
    • ID: yisghbfq
    Snippet: Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is mainly transmitted through respiratory droplets. The symptoms include dry cough, fever, and fatigue; however, high propagation, mutation, and fatality rates have been reported for SARS-CoV-2. This review investigates the structure of SARS-CoV-2, antiviral mechanisms, preventive strategies, and remedies against it. Effective vaccines have been developed by Pfizer (95% effective), As
    Document: Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is mainly transmitted through respiratory droplets. The symptoms include dry cough, fever, and fatigue; however, high propagation, mutation, and fatality rates have been reported for SARS-CoV-2. This review investigates the structure of SARS-CoV-2, antiviral mechanisms, preventive strategies, and remedies against it. Effective vaccines have been developed by Pfizer (95% effective), AstraZeneca (90% effective), Moderna (94.5% effective) vaccine, among others. However, herd immunity is also required. Probiotics play a major role in the gut health, and some are known to have therapeutic potential against viral infections. Their modes of antiviral activities include direct interaction with targeted viruses, production of antiviral metabolites, and immunomodulatory effects on the host. Hence, probiotics can be a useful prophylactic against COVID-19, and more studies are required on the effects of probiotics against other viral infections that may occur in future.

    Search related documents:
    Co phrase search for related documents
    • accessory protein and macrophage monocyte: 1
    • acid bacteria and actinobacteria proteobacteria: 1
    • acid bacteria and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5
    • acid bacteria and adaptive immunity: 1
    • acid bacteria and lta lipoteichoic acid: 1
    • acid bacteria and macrophage monocyte: 1
    • acquire immunity and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4
    • active factor and acute sars cov respiratory syndrome coronavirus: 1, 2
    • acute sars cov respiratory syndrome coronavirus and adaptive immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68
    • acute sars cov respiratory syndrome coronavirus and adaptive immunity activation: 1, 2, 3, 4, 5
    • acute sars cov respiratory syndrome coronavirus and lopinavir ribavirin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
    • acute sars cov respiratory syndrome coronavirus and lps stimulation: 1
    • acute sars cov respiratory syndrome coronavirus and lung cancer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65
    • acute sars cov respiratory syndrome coronavirus and lung disorder: 1, 2, 3
    • acute sars cov respiratory syndrome coronavirus and lysosomal ph: 1
    • acute sars cov respiratory syndrome coronavirus and macrophage inflammatory protein: 1, 2, 3, 4, 5, 6, 7, 8
    • acute sars cov respiratory syndrome coronavirus and macrophage inflammatory protein monocyte chemoattractant protein: 1, 2, 3
    • acute sars cov respiratory syndrome coronavirus and macrophage monocyte: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • adaptive immunity and lopinavir ribavirin: 1, 2